0
0
A groundbreaking international study has revealed a surprising biological link between newborn babies and individuals with Alzheimer’s disease: both groups exhibit high levels of the protein p-tau217, a well-established biomarker for Alzheimer’s, in their blood.
Researchers from the University of Gothenburg, collaborating with teams in Spain and Australia, analyzed blood samples from over 400 participants spanning healthy newborns, premature infants, young adults, older adults, and Alzheimer’s patients. The findings were striking—newborns had the highest concentrations of p-tau217, even surpassing those seen in Alzheimer’s patients. The highest levels were observed in premature infants, with concentrations gradually declining in the first months of life to reach typical adult levels.
Contrasting Roles in Health and Disease
Phosphorylated tau (p-tau217) is widely recognized as a marker for Alzheimer’s disease, where its accumulation is linked to the formation of toxic tau tangles and cognitive decline. In adults, elevated p-tau217 is believed to result from the buildup of beta-amyloid plaques in the brain. However, newborns do not exhibit these pathological changes. Instead, the elevated protein levels in infants are thought to reflect a healthy developmental process, supporting rapid brain growth and the formation of neural connections.
Earlier animal studies had hinted at a role for phosphorylated tau in early brain development, but this is the first time scientists have directly measured p-tau217 in human newborns. The results suggest that the protein may play a crucial part in building the brain, rather than signaling damage as it does in Alzheimer’s.
Implications for Future Alzheimer’s Treatments
One of the study’s most intriguing suggestions is that the newborn brain may possess natural mechanisms to tolerate or even benefit from high levels of phosphorylated tau—mechanisms that are lost with age. Understanding these protective processes could provide a roadmap for new therapies aimed at slowing or preventing Alzheimer’s disease. “If we can learn how the newborn brain keeps tau in check, we might one day mimic those processes to slow or stop Alzheimer’s in its tracks,” said lead researcher Fernando Gonzalez-Ortiz.
With plasma p-tau217 now approved by the FDA as a diagnostic tool for Alzheimer’s, these findings also underscore the need for careful interpretation of elevated tau levels, especially in clinical and epidemiological research.
“The same molecule, two dramatically different roles—one building the brain, the other marking its decline.”
Disclaimer:
This article summarizes recent scientific findings and is intended for informational purposes only. The research discussed is ongoing, and the clinical implications for Alzheimer’s diagnosis and treatment are not yet fully understood. Readers should consult healthcare professionals for medical advice or concerns regarding Alzheimer’s disease or infant health.
